- Home
- / StageZero Life Sciences
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
StageZero Life Sciences financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-10-29
Market Capitalization
$4.9 M
2024-10-29
Revenue
$3.8 M
FY, 2022
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|
| Revenue | 186.0K | 139.0K | 4.2M | 5.1M | 3.8M |
| Cost of goods sold | 1.2M | 862.0K | 3.2M | 3.6M | 3.1M |
| Gross profit | 498.0K | 1.7M | 921.0K | 1.5M | 657.0K |
| Gross profit margin, % | 1250.4% | 22.2% | 28.6% | 17.3% | |
| Operating expense total | 3.3M | 4.1M | 4.4M | 9.3M | 8.3M |
| Depreciation and amortization | 311.0K | 298.0K | 255.0K | 311.0K | 7.6M |
| EBITDA | (2.8M) | (2.4M) | (3.5M) | (7.8M) | (7.6M) |
| EBITDA margin, % | -1712.9% | -83.9% | -154.3% | -200.1% | |
| EBIT | (3.1M) | (2.7M) | (6.2M) | (6.2M) | (11.2M) |
| EBIT margin, % | -1927.3% | -149.3% | -122.6% | -295.6% | |
| Interest expense | 578.0K | 803.0K | 664.0K | 1.4M | 284.0K |
| Pre tax profit | (3.7M) | (3.5M) | (6.9M) | (7.5M) | (11.4M) |
| Net Income | (3.7M) | (3.5M) | (6.9M) | (7.5M) | (11.4M) |